Trial reportThe American journal on addictions
N-acetylcysteine (NAC) in young marijuana users: an open-label pilot study.
Trial report in The American journal on addictions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03018236 (The Effect of N-acetylcysteine), which is not on this map. Cited by 59 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.
Who cites it
59 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2019Pooled it
- A scoping review and meta-analysis of psychosocial and pharmacological treatments for cannabis and tobacco use among African Americans.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2017Pooled it
- Pharmacological treatments in pathological gambling.British journal of clinical pharmacology · 2014Pooled it
- Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.Schizophrenia bulletin · 2014Pooled it
- Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2014Pooled it
- Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers.Drug and alcohol dependence · 2021Trial
- The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial.Drug and alcohol dependence · 2018Trial
- Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation.Addictive behaviors · 2016Trial
- The effects of N-Acetylcysteine on frontostriatal resting-state functional connectivity, withdrawal symptoms and smoking abstinence: A double-blind, placebo-controlled fMRI pilot study.Drug and alcohol dependence · 2015Trial
- N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents.The American journal of psychiatry · 2012Trial
- A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence.The American journal on addictionsTrial
- The neuroimmune-glutamate hypothesis of addiction.Neuroscience and biobehavioral reviews · 2026Review
- Similarities and Differences in Neurobiology.Advances in experimental medicine and biology · 2025Review
- Treatment of Adolescent Cannabis Use Disorders.The Psychiatric clinics of North America · 2023Review
- Clearing up the smoke: Physical and mental health considerations regarding cannabis use in adolescents with cystic fibrosis.Pediatric pulmonology · 2023Review
- Treatment of Adolescent Cannabis Use Disorders.Child and adolescent psychiatric clinics of North America · 2023Review
- Old Dog, New Tricks: A Review of Identifying and Addressing Youth Cannabis Vaping in the Pediatric Clinical Setting.Clinical medicine insights. Pediatrics · 2023Review
- The Potential of N-acetyl Cysteine in Behavioral Addictions and Related Compulsive and Impulsive Behaviors and Disorders: a Scoping Review.Current addiction reports · 2022Article
- Stress- and drug-induced neuroimmune signaling as a therapeutic target for comorbid anxiety and substance use disorders.Pharmacology & therapeutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.